|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
Are your pharmaceuticals still safe to sell in Europe?
And how can you tell?
These questions have never been timelier. The new European Pharmacovigilance Risk Assessment Committee (PRAC for short) gets closer to full operation each day. Next year, when it hits full stride, U.S. drug exporters will find themselves playing under all-new rules.
It’s time you got up to speed — and doing so has never been easier.
In an hour or two of study, you’ll gain understanding of new EU pharmacovigilance rules, from preapproval through the life of a drug, plus insight into compliance in a new era. Specifically you’ll discover:
The PRAC will be responsible for investigating drug safety, reviewing risk management plans for new drugs, and advising when safety of a drug or class of drugs is in question. Will it be a tiger — or a paper tiger? You need to know — now.
Order Your Copy Today!
Table of Contents
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library – a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.
Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing